Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Organovo Holdings Inc

Organovo Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.4964
  • Today's Change-0.011 / -2.09%
  • Shares traded4.00k
  • 1 Year change-66.91%
  • Beta0.6156
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Organovo Holdings, Inc. is a clinical-stage biotechnology company. The Company is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues, as well as preclinical data. Its segments include research and development (R&D) and Mosaic Cell Sciences (Mosaic). It is also focused on building high fidelity, 3D tissues that recapitulate key aspects of human disease. It uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.

  • Revenue in USD (TTM)73.00k
  • Net income in USD-13.99m
  • Incorporated2012
  • Employees12.00
  • Location
    Organovo Holdings IncSuite 100, 11555 Sorrento Valley RoadSAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 224-1000
  • Fax+1 (302) 636-5454
  • Websitehttps://organovo.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Mosaic Immunoengineering Inc0.00-1.21m7.24m3.00---------0.1674-0.16740.00-0.89040.00----0.00-634.64-----------------14.05--------57.65------
BioNexus Gene Lab Corp9.18m-2.21m7.26m30.00--0.7474--0.7901-0.1108-0.11080.58070.54030.96477.195.77---23.17-3.83-27.98-5.0213.8814.55-24.02-3.044.87-118.920.00---10.60115.07-638.56--30.40--
NuCana PLC (ADR)0.00-37.54m7.29m25.00--1.44-----234.80-234.800.002.230.00----0.00-91.91-41.01-177.64-48.07------------0.0689------13.71---21.70--
Cannabis Bioscience Internatnl Hlgs Inc56.94m6.94m7.30m389.000.00130.00010.79150.12820.53280.53284.294.920.591762.811.45146,384.307.83--11.73--31.96--13.24--0.685650.750.0631--12.79--177.84------
Exicure Inc500.00k-8.17m7.32m5.00--4.54--14.64-4.72-4.720.28890.93230.0354----83,333.34-57.87-41.52-69.90-55.78-----1,634.40-290.95----0.3827---100.00---555.07------
National Graphite Corp0.00-1.97m7.33m0.00---------0.0221-0.02210.00-0.01930.00-------11,014.44-212.13---6,295.18---------------------1,432.70------
Organovo Holdings Inc73.00k-13.99m7.63m12.00--1.07--104.48-1.39-1.390.00690.46350.006--0.74113,650.00-115.47-54.25-136.97-58.4250.68---19,160.27-1,890.163.38--0.00---70.54-48.7815.00---11.87--
Cyclerion Therapeutics Inc0.00-10.47m7.94m1.00--0.8393-----4.261.270.003.490.00----0.00-103.82-72.70-150.23-86.96-------2,565.62----0.00---100.00--30.98------
Intelligent Bio Solutions Inc3.11m-10.16m7.99m13.00--0.78--2.57-39.72-39.722.312.410.25791.928.60239,366.90-84.45-71.59-156.10-144.3645.81---327.50-565.481.42--0.0592--147.58596.394.47------
Pulmatrix Inc11.39m-10.84m8.00m22.00--0.6009--0.7021-2.97-2.973.123.640.483--21.64517,818.20-45.97-46.91-52.76-58.12-----95.18-238.04----0.00--20.21116.6225.03--104.29--
TFF Pharmaceuticals Inc1.20m-19.39m8.01m19.00--1.28--6.66-7.95-7.950.46591.810.1043--3.5163,293.68-168.10-79.57-212.66-83.41-----1,612.04-8,687.66----0.00--48.01--33.13------
Correlate Energy Corp5.65m-34.51m8.02m19.00------1.42-0.8359-0.83590.1457-0.04611.50--11.12297,377.40-915.61-315.47-----6.4515.42-610.79-201.03---1.07----122.2046.12-78.54------
Cell MedX Corp0.00-142.49k8.03m0.00---------0.0021-0.00210.00-0.00280.00-------190.76-703.78------84.03---2,996.54---4.35-----100.00--71.22------
Data as of Sep 20 2024. Currency figures normalised to Organovo Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

9.04%Per cent of shares held by top holders
HolderShares% Held
Prescott Group Capital Management LLCas of 30 Jun 2024474.00k3.30%
The Vanguard Group, Inc.as of 31 Mar 2024353.61k2.46%
BlackRock Fund Advisorsas of 31 Mar 2024142.21k0.99%
Geode Capital Management LLCas of 30 Jun 2024110.36k0.77%
Renaissance Technologies LLCas of 30 Jun 202463.39k0.44%
Citadel Securities LLCas of 31 Mar 202446.38k0.32%
Morgan Stanley & Co. LLCas of 31 Mar 202438.78k0.27%
SSgA Funds Management, Inc.as of 31 Mar 202427.83k0.19%
XTX Markets LLCas of 31 Mar 202422.63k0.16%
Raymond James & Associates, Inc. (Invt Mgmt)as of 30 Jun 202419.62k0.14%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.